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A commercially available enzyme immunoassay devel-
oped to detect antibodies to a tuberculosis-associated
glycolipid antigen was evaluated for serologic diagno-
sis of tuberculosis. This was a multicenter study com-
paring the assay with other methods in 78 patients
with active pulmonary tuberculosis and in 54 controls
with non-tuberculous lung diseases. Sensitivities were
highest for sputum culture (91.0%), followed by im-
munoassay (79.5%), nucleic acid amplification (77.3%),
and finally acid-fast staining of sputum smear (60.3%).
Immunoassay and amplification, both rapid methods,
had similarly high sensitivity in smear-positive sub-
jects (89.4 and 88.9%, respectively); in smear-negative
subjects these two techniques showed low sensitivity
(64.5 and 60.0%, respectively). Concordance between
the two methods was relatively low (72.0%). With re-
gard to specificity, seven out of ten patients with old
tuberculosis had positive result by immunoassay (30%
specificity). In the control group, 10 out of 54 patients
had positive immunoassay result (72.2% specificity),
with notably limited specificity in the elderly. The tu-
berculous glycolipid assay is a rapid method suffi-
ciently sensitive for detection of tuberculosis infection,
even in smear-negative patients. Clin Chem Lab Med
2002; 40(8):832–836
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Abbreviations: AFB, acid-fast bacilli; COPD, chronic ob-
structive pulmonary disease; EIA, enzyme immunoas-
say; ImCRAC, immuno-cross-reactive antigenic com-
pound; LAM, lipoarabinomannan; NAA, nucleic acid
amplification; NTM, non-tuberculous mycobacteria;
TBGL, tuberculous glycolipid; TDM, trehalose 6’,6’-
dimycolate.
Introduction
Rapid and accurate diagnosis of tuberculosis is essential
for preventing spread of the disease. The most simple
and rapid method is sputum smear examination for acid-
fast bacilli (AFB) by microscopy, but about one-half of pa-
tients with pulmonary tuberculosis are smear-negative.
Culture of sputum is more sensitive, but can require up to
4 weeks in liquid culture and 8 weeks in solid culture.
Molecular methods for the diagnosis of tuberculosis
based on nucleic acid amplification (NAA) are rapid,
highly specific, and more sensitive than microscopic
sputum smear examination but are less sensitive than
culture in smear-negative cases (1). NAA is also ex-
pensive, technically complex, and requires meticulous
quality control. Serological detection of antibodies to
Mycobacterium tuberculosis (M. tuberculosis) could rep-
resent a simple, rapid and inexpensive diagnostic
method, and various antigens have been investigated in
this context (2, 3). In recent years some of these antigens
have been used in commercial kits. Antigen 60 (4, 5), 38
kDa antigen (6, 7), mycobacterial Kp90 immuno-cross-re-
active antigenic compound (ImCRAC) (8, 9), or lipoarabi-
nomannan (LAM) antigen (10–14) have been used as the
main antibody-detection antigen in many kits. However,
sensitivities and specificities have been highly variable,
ranging from 20 to 93% and from 62 to 100%, respec-
tively. Variability has been reported even using the same
kit, which may be attributable to differences between the
studied patient populations. Nonetheless, consistent
performance is crucial for a clinical diagnostic kit.
Tuberculous glycolipid (TBGL) antigens including
trehalose 6’,6’-dimycolate (TDM) and more hydrophilic
glycolipids purified from the H37Rv strain of M. tuber-
culosis have been used recently in a rapid enzyme im-
munoassay (EIA) kit for serodiagnosis of tuberculosis
(Determiner TBGL antibodies, Kyowa Medex, Tokyo,
Japan). This kit has been reported to have relatively
high sensitivity (81.1%) and excellent specificity
(95.7%) (15, 16). We conducted a multicenter study to
evaluate the clinical utility and the stability of this kit in
diagnosing active tuberculosis.
Materials and Methods
Patients and serum specimens
A total of 78 patients with pulmonary tuberculosis (mean age,
60.5 years; range, 18 to 94) were studied at the Department of
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Respiratory Diseases of Chubu National Hospital, the Depart-
ment of Respiratory Diseases of Higashi-Nagoya National
Hospital, the Department of Molecular Medicine and Clinical
Science of Nagoya University Hospital, and at the Department
of Clinical Laboratory of Kyoto University Hospital. No patient
was co-infected with human immunodeficiency virus (HIV).
Diagnosis of tuberculosis was based on the results of sputum
AFB smear and culture, radiographic findings, clinical symp-
toms and response to treatment.
Serum specimens from patients with active tuberculosis
were obtained upon admission before chemotherapy and
stored at –20°C until anti-TBGL antibody assay. Sputum spec-
imens for examination by smear and culture were obtained on
3 consecutive days immediately following admission. Spu-
tum smearing was processed for auramine-rhodamine stain-
ing, and culture for mycobacteria was carried out with a Septi-
Chek AFB system (Becton Dickinson, Cockeysville, MD, USA).
NAA was performed with the Amplicor PCR assay (Roche Di-
agnostics, Tokyo, Japan) on any of these three sputum speci-
mens according to the manufacturer’s instructions.
Control groups
Because a useful anti-TBGL antibody assay must be able to dif-
ferentiate patients with active tuberculosis from patients with
old tuberculosis or non-tuberculous respiratory disease, we
chose 10 patients with old pulmonary tuberculosis (mean age,
69.3 years; range, 34 to 84) and 54 patients with non-tubercu-
lous respiratory disease (mean age, 64.6 years; range, 18 to 89)
to investigate specificity of the kit. The patients with old tuber-
culosis had not received anti-tuberculous chemotherapy for at
least 3 years prior to entering the study, and showed stable
sclerotic lesions in chest radiographs and no detectable tuber-
cle bacilli in sputum specimens. The non-tuberculous respira-
tory disease group included 19 patients with neoplasms (17
with lung cancer and 2 with mediastinal tumors), 16 with non-
tuberculous lung infections (11 with bacterial pneumonia, 3
with pyothorax and 2 with lung abscess), 18 with chronic ob-
structive lung disease, 5 with bronchial asthma, 3 with pneu-
mothorax, and 3 with other lung diseases (1 each with intersti-
tial pneumonia, silicosis, and congestion). All control subjects
were HIV-seronegative.
NAA procedure
The NAA assay was performed according to the manufac-
turer’s instructions (17). Briefly, samples were treated with N-
acetyl-L-cysteine (NALC)-NaOH, lysed, and neutralized. Poly-
merase chain reaction (PCR) was performed with 50 µl of the
mixture using a GeneAmp PCR System 9600R thermal cycler
(Roche Diagnostics, Tokyo, Japan). After amplification, the
mycobacterial DNA was detected by an enzyme immunoas-
say. Absorbances were measured with a Nova Pavapath Mi-
croplate Reader (Bio-Rad, Richmond, CA, USA) at a wave-
length of 450 nm. Specimens with an absorbance value of at
least 0.35 were considered positive. Positive and negative am-
plification controls were included in each run.
TBGL assay
TBGL assay was performed according to the manufacturer’s
instructions as described previously (15). Briefly, 96-well
polystyrene microtiter plates (Polysorp immunoplates; Nunc,
Roskilde, Denmark) were coated with TBGL containing TDM
and minor glycolipids from the cell walls of the M. tubercu-
losis strain H37Rv by placing 25 µl of the antigen solution
(10 µg/ml in n-hexane) in each well and allowing the plate to
dry at room temperature. All samples, sera and calibration
samples were diluted 1:41 with dilution buffer, and 100 µl of
the diluted samples was added to each well. Plates were then
incubated for 60 min at room temperature. After the plates
were washed five times with buffer, horseradish peroxidase-
conjugated rabbit Fab’ raised against human immunoglobu-
lin (Ig)G was added to each well. Plates were incubated for
60 min at room temperature and were washed three times
with washing buffer. Then, 100 µl of 3,3’,5,5’-tetramethylben-
zidine (TMBZ) solution was added to each well and the plates
were incubated for 15 min at room temperature. At that time,
100 µl of 1 M H2SO4 was added to stop the enzymatic reac-
tion. Absorbance at 450 nm was measured with an MTP-120
plate reader (Corona Electric, Tokyo, Japan). Samples with at
least 2.0 U of antibody per milliliter were considered posi-
tive.
Statistical analysis
Differences in performance between the various laboratory
tests for M. tuberculosis infection were analyzed by the chi-
squared test.
Results
Positivity rate of AFB smear, sputum culture, NAA and
anti-TBGL antibody titers in patients with active
tuberculosis
Table 1 shows positivity rates in active tuberculosis for
the AFB smear, sputum culture, NAA with Amplicor
PCR and anti-TBGL antibody titers. Sensitivity was
highest for culture (91.0%), followed by TBGL assay
and NAA (79.5 and 77.3%), and finally the AFB smear
(60.3%). When two rapid and sensitive methods, TBGL
assay and NAA, were compared in active tuberculosis
(Table 2), the sensitivity of TBGL assay was nearly the
same as that of NAA, both in smear-positive and -neg-
ative individuals. Both methods showed high sensitiv-
ity in smear-positive individuals but were significantly
less sensitive in smear-negative subjects. NAA, but not
TBGL assay, showed significantly higher sensitivity in
culture-positive than culture-negative subjects. Forty-
eight individuals had positive results for both tests, and
six had negative results for both. A discrepancy was
noted between these tests in 21 individuals. Accord-
ingly, TBGL assay and NAA results were 72.0% concor-
dant.
Table 1 Positivity rate of AFB smear, culture, NAA, and TBGL
assay in active tuberculosis.
Test No. of subjects Sensitivity (%)
Total Positive Negative
AFB smear 78 47 31 60.3
Culture 78 71 7 91.0
NAA 75 58 17 77.3
TBGL assay 78 62 16 79.5
NAA, nucleic acid amplification by Amplicor PCR. In the TBGL
assay, the cut-off value was set at 2.0 U/ml.
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Anti-TBGL antibody titers in control subjects
In the group with old tuberculosis, the positivity rate
was 70%, which corresponds to 30% specificity
(Table 3). Statistical analysis revealed a significant dif-
ference (89.5 vs. 62.9%; p=0.037, by chi-squared test)
between patients with a neoplasm and those with an-
other respiratory disease. As for age, this test showed
higher sensitivity in younger patients (age 59 years or
less) than older patients (age 60 years or more), but the
difference fell short of significance (88.2 vs. 64.9%;
p=0.075, by chi-squared test).
Discussion
Rapid detection of M. tuberculosis in specimens from
individuals suspected to be infected has been a main-
stay of diagnosis of tuberculosis. While NAA was
hoped to satisfy this need, the sensitivity of NAA is lim-
ited in smear-negative specimens. Moreover, the cost
of equipment and reagents is prohibitive for many hos-
pital laboratories.
Several serologic tests using appropriate antigens
have been developed for sensitive and specific diagno-
sis of tuberculosis. While speed, simplicity and low
cost of these methods make them suitable screening
tests, sensitivity and specificity have varied. Pot-
tumarthy et al. (18) reported performance of seven
tests for serologic diagnosis of tuberculosis. The Tu-
berculosis IgA EIA (Kreatech Diagnostics, Amsterdam,
The Netherlands), an EIA kit that detects IgA antibody
to mycobacterial Kp90 ImCRAC, had the highest sensi-
tivity (57%) in 36 active tuberculosis patients (12/36
AFB smear-positive) but showed a very poor specificity
of 62% in negative controls. These authors concluded
that the best performing kit was ICT Tuberculosis (ICT
Diagnostics, Balgowlah, New South Wales, Australia),
an immunochromatographic assay using five highly
purified antigens, including 38 kDa antigen, with the
next best being Pathozyme-Myco IgG (Omega Diag-
nostics, Alloa, Scotland), an EIA kit using LAM antigen
(present in the cell wall) and recombinant 38 kDa anti-
gen. Respective sensitivities were 41% and 55% in ac-
tive tuberculosis, while specificities were 96% and 89%.
Chiang et al. (19) compared three specific mycobacter-
Table 3 Positivity rate of TBGL assay in old tuberculosis and non-tuberculous pulmonary diseases.
Source of samples Average age±SD (years) No. of subjects Specificity (%)
Total Positive Negative
Old tuberculosis 10 7 3 30
Other respiratory diseases 64.6±15.7 54 15 39 72.2
Neoplasm 66.0±12.2 19 2 17 89.5
Non-tuberculous infection 59.3±19.0 16 5 11 68.8
COPD 72.0±14.7 8 2 6 75
Bronchial asthma 66.2±7.1 5 2 3 60
Pneumothorax 45.0±6.5 3 1 2 66.7
Others 80.7±3.2 3 3 0 0
Agea (range, years)
59 years or less 17 2 15 88.2
60 years or more 37 13 24 64.9
a The 54 patients with other respiratory diseases were categorized according to age;
COPD: chronic obstructive pulmonary disease.
Table 2 Comparison of TBGL assay and NAA according to AFB smear and culture results.
TBGL assay NAA
Total Positive Negative Sensitivity Total Positive Negative Sensitivity
(%) (%)
AFB smear
Positive 47 42 5 89.4 0.008 (S) 45 40 5 88.9 0.003 (S)
Negative 31 20 11 64.5 30 18 12 60.0
Culture
Positive 71 56 15 78.9 0.669 (NS) 68 54 14 79.4 0.180 (NS)
Negative 7 6 1 85.7 7 4 3 57.1
a Significantly different results are indicated by a p-value of ≤ 0.05. S, statistically significant;
NS, not statistically different.
p-Value for AFB
smear- or culture-
positive vs. nega-
tive individualsa
p-Value for AFB 
smear- or culture-
positive vs. nega-
tive individualsa
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ial antigens in the diagnosis of tuberculosis corre-
sponding to three EIA kits. These included Anda TB
(Anda Biologicals, Strasbourg, France), which mea-
sures IgG antibody to antigen 60; Pathozyme-TB Com-
plex (Omega Diagnostics), which measures IgG anti-
body to 38 kDa antigen; and Tuberculosis IgA EIA
(Kreatech Diagnostics). By a receiver operating charac-
teristic (ROC) analysis, sensitivities of these kits were
80.77, 64.12, and 62.58% in 312 active tuberculosis pa-
tients (47.4% AFB smear-positive), while specificities
were 88.40, 80.74, and 66.30%, respectively.
Serological detection of antibodies against LAM, in-
cluding a commercially available dot-blot assay kit
(MycoDot; Genelabs, Geneva, Switzerland) has been
evaluated extensively (10–14). A wide range of sensi-
tivity of anti-LAM IgG was seen among HIV-negative
patients with active tuberculosis, ranging from 21.5 to
93%; sensitivity was generally lower in HIV-positive pa-
tients. In contrast, specificity was excellent, ranging
from 84 to 100%. In a Japanese study of the MycoDot
test, sensitivity and specificity were 79 and 96%, re-
spectively (14).
Improvement of serodiagnosis for tuberculosis re-
quires advances enhancing reliability of the results.
Heterogeneity of antibody responses to protein anti-
gens of M. tuberculosis was reported (20). In this re-
port, heterogeneity between subjects of antigen recog-
nition in general, rather than recognition of particular
antigens, appears to characterize the antibody re-
sponse. When a cell wall component, LAM, has been
investigated as a candidate antigen for serodiagnosis,
a dot-blot assay kit for antibodies against LAM (My-
coDot) also showed variable sensitivity and specificity
(10–14). As mentioned above, this kit showed a good
sensitivity and excellent specificity in one Japanese
population but another study is necessary to confirm
reliability (14). This kit, dot-blot immunoassay using vi-
sual detection, requires only 20 min to carry out reac-
tions. Results are read with the naked eye, using no
special apparatus. However, it does not provide quanti-
tative information about antibody titers, which may
lead to misreading of weakly positive results.
The TBGL assay kit uses other cell wall components,
glycolipids composed of TDM and a more hydrophilic
glycolipid purified from H37Rv (15). Quantitative anti-
body titers can be obtained with this EIA kit. One study
showed a relatively high sensitivity (81.1%), nearly
equal to that in the MycoDot study (16). In the clinical
setting, the TBGL kit required evaluation as a rapid di-
agnostic test for tuberculosis, especially in comparison
with other rapid methods (AFB smear and NAA). This
was our focus in the present study. Sensitivity in our
study was 79.5% considering all patients with active tu-
berculosis, which was almost equal to that obtained
previously. As indicated in Table 2, sensitivity was
89.4% in smear-positive and 60.6% in smear-negative
patients. Variability of antibody responses against gly-
colipids and the glycolipid component of the tubercu-
losis bacilli isolated from patients has been reported.
Increased sensitivity in smear-positive patients may
suggest that the titer of antibodies against glycolipid
may depend on the number of tuberculosis bacilli in
the lesion, with low numbers giving a false-negative re-
sult. To improve the sensitivity of TBGL assay kit, vari-
ous combinations of antigens such as LAM and protein
antigens together with the glycolipids should be tested
as detection antigens (3, 8, 21).
The anti-TBGL antibodies assay should be used
mainly to differentiate patients with active tuberculosis
from others with non-tuberculous respiratory disease,
and we examined specificity of this. Specificity in our
study (72.2%) was somewhat lower than in a previous
study with a similar age distribution (85.0%) (16). In el-
derly subjects, the positivity rate was somewhat
higher. The reason for apparent low specificity is not
clear, but it actually might involve the high prevalence
of tuberculous infection among the elderly in Japan.
Maekura et al. (16) also reported excellent specificity of
the TBGL assay in young, healthy subjects (95.7%); we
found similarly high specificity in similar subjects
(92.3%; unpublished data). As an additional reason, the
composition of TBGL is similar in M. tuberculosis and
non-tuberculous mycobacteria (NTM) and cross-reac-
tivity was reported in a previous study (16). The occult
infection with NTM may affect the results of the TBGL
assay.
Among 10 patients with old tuberculosis, we found
70% to be positive by the TBGL assay. All of these pa-
tients showed fibrocalcified old tuberculous scars in
chest roentgenograms. Maekura et al. (16) reported
that anti-TBGL antibody titers were significantly higher
in advanced lesions, and that, while high titers de-
creased significantly after 6 months of antituberculous
chemotherapy, they did not fully return to the normal
range. In other reports, about 3 years were required for
antibody tests using tuberculous antigens to become
negative. Similarly, Chiang et al. (19) reported high
positivity rates, 53% and 49%, in their fibrocalcific tu-
berculosis group. The old tuberculosis group may have
had extensive disease, with fibrocalcific lesions re-
maining in the lung, causing positive reactions with
anti-TBGL antibody.
Usefulness of TBGL assay compared to NAA is an
important issue for rapid diagnosis of active tuberculo-
sis. In smear-positive individuals, both methods can
detect mycobacterial disease with excellent sensitivity.
However, reliability of such rapid diagnostic kits is par-
ticularly important to differentiate smear-negative tu-
berculosis from other pulmonary diseases, given the
long time required for culture. In our study, sensitivity
of the two tests was almost equal in smear-positive and
-negative individuals but showed relatively low con-
cordance. In a study comparing NAA (Amplicor) with a
serologic test (Detect-TB, Biochem ImmunoSystems,
Montreal, Canada) in patients with minimal pulmonary
tuberculosis (22), respective sensitivity was 42% and
33%, which is considerably lower than in our smear-
negative patients with active tuberculosis (60.6 and
56.3%, respectively). Patients with particularly minimal
lesions might have predominated in that earlier com-
parison but sensitivity was 73.5% in both smear- and
culture-negative patients in that previous study with
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TBGL assay (16). NAA is costly and complex, and also
requires much ongoing quality control effort; further,
results depend upon specimen quality.
In the present study we showed that the TBGL assay
kit is sufficiently sensitive for use in rapid detection of
tuberculosis infection even in smear-negative patients.
However, further efforts are needed to increase sensi-
tivity, such as testing of multi-antigen cocktails.
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